Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus

Autor: Tingli Sun, Lina Wang, Lijie Zhao
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Zdroj: Therapeutics and Clinical Risk Management
ISSN: 1178-203X
Popis: Lijie Zhao,1 Tingli Sun,2 Lina Wang1 1Department of Geriatrics, 2Department of Nephrology, General Hospital of Daqing Oil Field, Daqing, China Abstract: Sitagliptin improves glycemic control in type 2 diabetes mellitus (T2DM) patients but its side effects are undesirable. Chitosan oligosaccharide (COS) is expected to improve the therapeutic result as a natural product. A total of 200 elderly T2DM patients were evenly assigned into four groups: sitagliptin group (SG), receiving sitagliptin 100 mg/day; COS group (CG), receiving COS 100 mg/day; combination therapy of sitagliptin and COS group (SCG), receiving both sitagliptin and COS 100 mg/day; and placebo group (PG), receiving placebo 100 mg/day. After 42-week therapy, biochemical indices and clinical parameters for the alterations from start points were analyzed. The related molecular mechanism was tested by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot at cell level. Lower risk of hypoglycemia was found in the SCG group when compared with SG and other groups (P2.5% (P
Databáze: OpenAIRE